Intrexon Corporation (Public - NYSE: XON) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
Macroeconomic Uncertainty in the US Seafood Market United States
The dual impact of disputed refunds under IEEPA and new tariff threats under Section 301 creates a commercial stalemate.
The regulatory and fiscal framework applied to seafood imports in the United S...
Intrexon Corporation
Shareholder/Associate at:
Print
